Edition:
United Kingdom

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Global Market

6.85USD
17 Jan 2019
Change (% chg)

-- (--)
Prev Close
$6.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
28,823
52-wk High
$11.47
52-wk Low
$4.41

Latest Key Developments (Source: Significant Developments)

Redhill Biopharma Announces Final Results From Phase II Study With Bekinda For IBS-D
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Redhill Biopharma Ltd ::REDHILL BIOPHARMA ANNOUNCES FINAL RESULTS FROM PHASE II STUDY WITH BEKINDA® FOR IBS-D.REDHILL BIOPHARMA - INDEPENDENT REVIEW & ANALYSIS OF FINAL RESULTS CONFIRMED THAT PHASE II STUDY WITH BEKINDA 12 MG SUCCESSFULLY MET PRIMARY ENDPOINT.REDHILL BIOPHARMA - PLANS TO MEET WITH FDA IN H1 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D.  Full Article

Redhill Biopharma provides 2017 year-end business update
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Redhill Biopharma Ltd ::REDHILL BIOPHARMA PROVIDES 2017 YEAR-END BUSINESS UPDATE.REDHILL BIOPHARMA LTD - ‍COST REDUCTION PLAN IS IN PLACE TO GRADUALLY REDUCE AVERAGE QUARTERLY CASH BURN RATE IN 2018 TO APPROXIMATELY $8.5 MILLION​.REDHILL BIOPHARMA LTD - FOCUSING ON DELIVERING PHASE III DATA READ-OUTS WITH RHB-104 FOR CROHN'S DISEASE AND TALICIA FOR H. PYLORI INFECTION.  Full Article

Redhill biopharma Q3 ‍loss per ordinary share US$0.09
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Redhill Biopharma Ltd :Redhill Biopharma reports 2017 third quarter financial results.Q3 revenue $1.5 million.Redhill Biopharma Ltd - ‍decrease quarterly cash burn rate and continued revenue growth are expected in 2018​.Redhill Biopharma Ltd - ‍top-line results from first Phase III study with RHB-104 for Crohn's disease (MAP US study) expected in mid-2018​.Redhill Biopharma - ‍top-line results from confirmatory Phase III study with Talicia (RHB-105) for treatment of H. Pylori infection, expected in H2/2018​.Redhill Biopharma Ltd qtrly ‍loss per ordinary share us$0.09​.  Full Article

RedHill Biopharma prices public offering of its American Depositary Shares
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Redhill Biopharma Ltd : :RedHill Biopharma prices public offering of its American Depositary Shares.RedHill Biopharma Ltd - ‍pricing of its underwritten public offering for a total number of 4.1 million ADSS at a public offering price of $5.50 per ADS​.  Full Article

Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Redhill Biopharma Ltd ::Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines.Redhill Biopharma Ltd - ‍PDUFA date is expected to be set by FDA for first half of 2018 for Rizaport​.  Full Article

IntelGenx and Redhill Biopharma resubmit Rizaport NDA to FDA
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - IntelGenx Technologies Corp :Intelgenx and Redhill Biopharma resubmit Rizaport new drug application to the FDA.Intelgenx Technologies Corp- ‍co, Redhill Biopharma have resubmitted new drug application to U.S. FDA for Rizaport 10 mg​.Intelgenx-‍if Rizaport NDA resubmission is complete & permitted a full review by FDA, PDUFA date is expected to be set by agency for first half of 2018​.  Full Article

RedHill Biopharma receives Notice of Allowance for a new U.S. patent covering RHB-104
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Redhill Biopharma Ltd :RedHill Biopharma receives Notice of Allowance for a new U.S. patent covering RHB-104.RedHill Biopharma - ‍enrollment in phase III study with RHB-104 for Crohn's Disease to be completed in Nov 2017, top-line results expected in Q3/2018​.RedHill Biopharma Ltd - ‍new patent, covering RHB-104 for relapsing-remitting multiple sclerosis (MS), is expected to be valid until 2032, once granted​.  Full Article

RedHill Biopharma receives FDA Orphan Drug Designation for MESUPRON for pancreatic cancer
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Redhill Biopharma Ltd :RedHill Biopharma receives FDA Orphan Drug Designation for MESUPRON for pancreatic cancer.RedHill Biopharma says it ‍is also evaluating utilization of MESUPRON in several inflammatory gastrointestinal indications​.  Full Article

UPDATE 1-Tel Aviv shares slide 5 pct in worst day since 2011

JERUSALEM, Dec 23 Israeli stocks slid on Sunday, posting their worst daily performance in more than seven years in a broad selloff that followed declines on Wall Street late last week.

No consensus analysis data available.